BioLine RX Ltd

BioLine RX Ltd(BLRX)の株式分析

$1.730

-0.037 (-2.15%)終値時点

Loading chart…
高値
1.750
始値
1.715
出来高加重平均価格
1.73
出来高
7.76K
時価総額
45.57M
安値
1.709
売買代金
13.42K
EV/EBITDA(TTM)
-0.45

BioLine RX Ltd is an Israel-based clinical-stage biopharmaceutical company focused on oncology. The Company is commited into in-license novel compounds, develop them through clinical stages, and then partner with pharmaceutical companies for further clinical development andcommercialization. The Company is commited into two projects: Motixafortide (BL-8040), which is a cancer therapy platform , and AGI-134, an immunotherapy treatment.

www.biolinerx.com

AI分析 of BioLine RX Ltd (BLRX)

売り

BioLine RX Ltd is not a good buy right now due to its current price of $1.73, a very low RSI of 11.115 indicating oversold conditions, and a staggering 49.71% decline over the past year. The company also reported a widening net loss of $4.3 million in Q2 2026, which raises concerns about its financial health and sustainability.

アナリスト評価(4)

上値余地 +593.64%
買い
4 買い
0 中立
0 売り
現在: 1.73
安値
12.00
平均
12.00
高値
12.00

Jones Trading

2025-04-02

目標株価

—

中立

HC Wainwright & Co.

2025-03-31

目標株価

$26

強い買い

HC Wainwright & Co.

2024-11-25

目標株価

$9

強い買い

HC Wainwright & Co.

2024-11-06

目標株価

$21

強い買い

Jones Trading

2024-09-04

目標株価

$2

強い買い

バリュエーション指標

BioLine RX Ltd(BLRX)の現在の予想PERは93.46で、5年平均は15.21です。

予想PER

大幅な割高
5年平均 P/E
15.21
現在のP/E
93.46
割高
53.08
割安
-22.67

予想EV/EBITDA

適正
5年平均 EV/EBITDA
-1.03
現在のEV/EBITDA
-0.45
割高
0.32
割安
-2.39

予想PSR

適正
5年平均 P/S
14.00
現在のP/S
3.96
割高
56.66
割安
-28.65

Alphio AI による BLRX の価格シナリオ

シナリオ価格は本年の最終月次予想レンジです。確率はモデルの固定ウェイト(25 / 50 / 25)であり、保証ではありません。

強

強気

強気 · 25%BLRX

$4.97

シナリオ価格

基

基本

基本 · 50%BLRX

$4.62

シナリオ価格

弱

弱気

弱気 · 25%BLRX

$4.26

シナリオ価格

イベントタイムライン

2026-09-25 (ET)

17:00:00

Company Not Selling 2.02M American Depositary Shares

2026-08-31 (ET)

16:30:00

Major Averages Decline as September Rate Hike Probability Rises to 60%

12:00:00

Major Averages Broadly Lower as Oil Prices Rise

09:00:00

Investors Pull Back Amid Geopolitical and Inflation Concerns

07:30:00

BioLineRx Reports Q2 Revenue of $294,000

ニュース

BLRX のよくある質問 — Alphio AI が回答

BioLine RX Ltd is an Israel-based clinical-stage biopharmaceutical company focused on oncology. The Company is commited into in-license novel compounds, develop them through clinical stages, and then partner with pharmaceutical companies for further clinical development andcommercialization. The Company is commited into two projects: Motixafortide (BL-8040), which is a cancer therapy platform , and AGI-134, an immunotherapy treatment. It operates in the Healthcare sector.

BioLine RX Ltd is not a good buy right now due to its current price of $1.73, a very low RSI of 11.115 indicating oversold conditions, and a staggering 49.71% decline over the past year. The company also reported a widening net loss of $4.3 million in Q2 2026, which raises concerns about its financial health and sustainability.

4 analysts cover BLRX: 4 rate it Buy, 0 Hold and 0 Sell. The average price target is 12.00.

コミュニティ

もっと見る ↗

投稿はまだありません

登録またはログインして議論に参加

関連記事

本ページは調査目的であり、投資助言ではありません。モデルは誤ることがあります。過去の実績は将来の成果を保証しません。

取引を始める